Tag Archive for: Novo Holdings

Novo Holdings portfolio company Numab Therapeutics announces Johnson & Johnson (‘J&J’) to acquire its wholly-owned subsidiary Yellow Jersey Therapeutics

/in

Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights, and will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications NM26 is a Phase 2-ready bi-specific antibody from Numab’s pipeline of candidates discovered and engineered using […]

Read more

Novo Holdings Boston office named a 2024 Best Place to Work by the Boston Business Journal

/in

Investment firm’s connection to the Novo Nordisk Foundation provides a strong sense of purpose, report employees Award highlights collaborative, respectful workplace, and comprehensive employee benefits Boston, US, 23 May 2024 – Novo Holdings, a leading life science investor, today announced that its Boston office has been named a 2024 Best Place to Work by the Boston Business […]

Read more

Novo Holdings and A.P. Moller Holding back CIRCTEC, a leader in pyrolysis for sustainable end-of-life tyre recycling, in a €150 million financing round

/in

Novo Holdings and A.P. Moller Holding have enabled a €150 million fundraise for CIRCTEC by leading with a €75 million equity investment. Financing includes €22.5 million of grants awarded by the Government of the Netherlands. The funding enables CIRCTEC to construct Europe’s largest end-of-life tyre pyrolysis recycling facility in Delfzijl, the Netherlands. The construction of […]

Read more

Novo Holdings to acquire majority stake in Single Use Support

/in

Novo Holdings A/S (“Novo Holdings”) today announced that it has agreed to acquire a majority stake in Single Use Support, a fast-growing life science tools company providing advanced technology solutions for the pharmaceutical production process. Novo Holdings will acquire an approximately 60% controlling stake, alongside the two company founders who will each retain 10% and […]

Read more

Commit Biologics launches with €16m seed financing to pioneer complement system activation to treat cancer and autoimmune disease

/in

Financing led by Bioqube Ventures and Novo Holdings Commit is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases Its unique bispecific technology (BiCE™) engages the complement system, unleashing its power to selectively kill target cells Spin-out from Aarhus University in Denmark, a world leader […]

Read more